Devyser Diagnostics AB (DVYSR)

Currency in SEK
63.00
0.00(0.00%)
Closed·

DVYSR Earnings

Latest Release
Jul 20, 2026
EPS / Forecast
-- / 0,68
Revenue / Forecast
-- / 77,9M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/0,417--/70,47M----Free Sign Up
2026/06--/0,680--/77,90M----Free Sign Up
2026/030,170/0,04061,80M/63,70M+325%-2,98%Free Sign Up
2025/120,800/0,59772,00M/78,40M+34,07%-8,16%Free Sign Up
2025/09-0,170/0,27056,40M/72,17M-162,96%-21,85%Free Sign Up
2025/060,080/-0,13267,40M/61,93M+160,61%+8,83%Free Sign Up
2025/03-1,24/-0,40354,80M/57,18M-207,46%-4,16%Free Sign Up
2024/12-0,200/-0,68064,20M/63,98M+70,59%+0,34%Free Sign Up
2024/09-1,40/-1,3748,70M/48,80M-2,19%-0,2%Free Sign Up
2024/06-1,40/-1,4053,20M/53,20M0%0%Free Sign Up

All numbers in SEK

Devyser Diagnostics AB Earnings Call Summary for Q2/2026

  • Q2 revenue fell 11% to 60M SEK vs 67M SEK prior year, missing analyst estimates of 77.9M SEK due to weak distributor orders from Thermo Fisher.
  • Posted fifth consecutive quarter of positive EBIT at 0.5M SEK; gross margin of 76% impacted by one-time inventory adjustment, normalized at 80%.
  • Company ended quarter with 81M SEK cash and secured 70M SEK credit facility from SEB; operating cash flow reached 12.3M SEK in the quarter.
  • Management expects transplant segment weakness through H2 2026 with recovery in 2027; hereditary products showed strong growth, up 14% year-over-year.
  • Launched Chimerism Plus product to strengthen competitive position; current 30% growth target expires end-2026, new guidance to be provided later.
Last Updated: 2026/07/20, 09:36
Read Full Transcript

FAQ

What Is Devyser Diagnostics AB's Earnings Per Share (TTM)?

The Devyser Diagnostics AB EPS (TTM) is 0,89.

When Is The Next Devyser Diagnostics AB Earnings Date?

Devyser Diagnostics AB will release its next earnings report on Nov 03, 2026.

What Is Devyser Diagnostics AB’s Revenue Forecasts For Upcoming Quarters?

Devyser Diagnostics AB’s revenue forecast is 70.47M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.